Clinical Trial Update: Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and pharmacodynamic comparison of biphasic insulin aspart 30 and biphasic human insulin 30 in adults with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic Human Insulin 30 (biphasic human insulin 30)
• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED